missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD21/CD35 Monoclonal Antibody (eBio8D9 (8D9)), eBioscience™, Invitrogen™
Rat Monoclonal Antibody
Marque: Affymetrix eBioscience 14-0211-95
Les retours ne sont pas autorisés pour ce produit.
Afficher la politique du retour.
Description
The MAb eBio8D9 reacts with an eptiope shared by mouse CD21 (CR2) and CD35 (CR1). CD21 and CD35 are alternatively spliced transcripts from the Cr2 gene, which produce cell-surface proteins of 145 and 190 kDa, respectively. CD21 and CD35 are expressed by mature B cells, but not on thymocytes, peripheral T cells, erythrocytes or platelets. Furthermore, there is some evidence which demonstrates their expression on macrophages. CD21 is a receptor for the complement component C3d and Epstein-Barr virus (EBV). In association with CD19 and CD81, CD21 also participates in B-cell activation through the B cell receptor. Cr2-deficient mice display impaired inflammatory and humoral immune responses in vivo. The anti-mouse CD21/35 MAb clones eBio4E3 and eBio8D9 do not cross-block each other, suggesting that they bind to different epitopes.
CD21/CD35 Monoclonal antibody specifically detects CD21/CD35 in Mouse samples. It is validated for Flow Cytometry, Functional Assay, Western Blot
Spécification
| CD21/CD35 | |
| Monoclonal | |
| 0.5 mg/mL | |
| PBS with 0.09% sodium azide; pH 7.2 | |
| P19070 | |
| Rat | |
| 10 mg | |
| Primary | |
| Mouse | |
| Antibody | |
| IgG2a λ |
| Flow Cytometry, Functional Assay, Western Blot | |
| eBio8D9 (8D9) | |
| Unconjugated | |
| Cr2 | |
| C3b/C4b receptor; C3-binding protein; C3DR; CD21; CD35; CD35 antigen; complement C3d receptor; complement receptor 2; complement receptor type 1; complement receptor type 2; Cr1; Cr-1; Cr2; Cr-2; EBV receptor; expressed in B lymphocytes | |
| Affinity chromatography | |
| RUO | |
| 12902 | |
| 4° C | |
| Liquid |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu